PCN87 Cost Effectiveness Evaluation of Vemurafenib, an Orphan Drug for Braf Mutant Metastatic Melanoma

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.2127
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

PLoS ONE
Multidisciplinary
2015English

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Metastatic Melanoma and Vemurafenib: Novel Approaches

Rare Tumors
OncologyHistology
2012English

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

Oncologist
Cancer ResearchMedicineOncology
2013English

Targeting Epigenetics for Treatment of BRAF Mutated Metastatic Melanoma With Decitabine in Combination With Vemurafenib: A Phase Lb Study

Oncotarget
Oncology
2017English

Detection of Mutant BRAF Alleles in the Plasma of Patients With Metastatic Melanoma

Journal of Molecular Diagnostics
Forensic MedicinePathologyMolecular Medicine
2007English

Simultaneous Treatment of Severe Vemurafenib-Induced Uveitis and Metastatic Melanoma

Journal of Clinical & Experimental Ophthalmology
2016English

Economic Evaluation and Cost-Effectiveness Threshold in Practice of Decision-Making on Orphan Drug Reimbursement in Poland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancers
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy